The proportion of female speakers increased over time, but they remain underrepresented in procedural and other specialties.

In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...

The findings are consistent with prior research showing that counties lacking these services have poorer CV outcomes.

The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.

With the pandemic having worsened burnout and intent to leave, the authors say keeping and supporting the workforce is ...

Sugar substitutes, substance abuse, GLP-1 drugs, and the biggest clinical trials of the year—each had their place in our top 10.

This month, as we wrap up 2024, our top 10 list covered quite broad ground. There were reimbursement woes and social media shifts, plus good news for the dual GIP/GLP-1 drug tirzepatide ...

In 2024, the field of heart failure continued to see emerging positive data on therapies for heart failure with preserved ejection fraction (HFpEF), transthyretin amyloidosis with cardiomyopathy (ATTR ...

Be it bullying, offensive language, or misuse of power, the cardiovascular community took a stand against disruptive behaviors this year, with some cardiovascular societies proactively issuing ...

For general cardiology and prevention, the year 2024 was all about novel treatments for new targets—be those lipoprotein(a), glucagon-like peptide-1 (GLP-1), or angiotensinogen. But at the same time, ...

Medicine is a balancing act, a mosaic of competing priorities. Just this week, I wrapped up a challenging coronary intervention and hurriedly planned a TAVR case before racing against the clock to ...